Santo Domingo, RD.
The President of the Dominican Republic, Luis Abinader, asked his stadium homologue Joe Biden not to allow the hope of new attempts to realize the United States over the vacancy of AstraZeneca, against covid-19, to kill the Dominican Republic.
Abinader colgó the message containing a publication of the New York Times periodical that states that the United States has thousands of doses of the AstraZeneca vaccine, hoping for the results of the tests, while the countries that authorize the vaccine pennens.
‘Pdte. @JoeBiden, minor country lands and traditional allies of the EE. UU., Como Rep. Dom., We approved the AstraZeneca vaccine and the emergency room. Never allow the hope of new attempts to demoralize our immediate access to this vacancy. Not just series ”, written by Luis Abinader.
Agreed to the diary, the clinical trial that conducts the EE. UU., Has not reported results and the company has not applied for the authorization to use the Food and Drug Administration (EMA). While AstraZeneca has asked the Biden administration to allow the dose to be studied in the European Union, it has not complied with its original summons compromises and the holiday campaign has been trodden heavily.
Ante denounces that the AstraZeneca vaccine could provoke thromboembolic events in countries such as Italy, Denmark, Norway and Iceland, as well as Estonia, Lithuania, Latvia and Luxembourg, to decide to suspend immunization with all doses or only in specific cases. The PRAC Committee of the European Medicines Agency finalizes its inquiry into the cases reported.
While the Dominican Republic Health Cabinet announced that since this week, on the 27th of this month, the evacuation process, initiated on February 16th, the first vacancy lot of India, will continue on citations.
Formally, starting from the 24th of March, we will start applying the second dose.
In October of this year, the governor of Luis Abinader signed an agreement with the British company AstraZeneca to acquire 10 million doses of his AZD1222 vaccine, developed together with the University of Oxford, for a value of 40 million dollars.